logo
The Battle Over the World's Richest Shipwreck and its $16 Billion Treasure

The Battle Over the World's Richest Shipwreck and its $16 Billion Treasure

Yahoo18 hours ago

Researchers have finally confirmed that a long-sunken hulk off the coast of Colombia is none other than the San José. The legendary Spanish galleon, which vanished beneath the waves of the Caribbean 300 years ago, has been dubbed the 'world's richest shipwreck.' Now the big question is, who does the treasure belong to?
The San José was first launched in 1698 and was the flagship of the Spanish treasure fleet. In 1708, it was carrying gold and jewels from Peru to Spain that would help fund the War of Spanish Succession. As the ship approached Cartagena, Colombia, British naval forces attacked. During the melee, the gunpowder stores on the San José ignited, sinking the ship. Nearly 600 crew members perished as the ship went down with its vast cargo of gold, silver, emeralds, pearls, and other treasures.
For centuries, the wreck remained lost beneath the sea. Two groups claim they discovered the famous shipwreck. U.S. salvage company Glocca Morra (now Sea Search Armada) insists that it first found the location of the ship in 1981. Then, in 2015, the Colombian navy, working with marine archaeologists, located the actual remains of the galleon using underwater drones.
At a depth of around 600m, it is too deep for divers to access. This made it hard for researchers to confirm that it is definitely the San José. The Colombian navy has been using remotely operated vehicles to survey the wreck. The key to proving that it is the San José has been the gold coins scattered on the ocean floor.
​​The lead author of a new study, Daniela Vargas Ariza, explained how these coins allow dating of the wreck and its demise through a process of elimination. These particular coins, known as "cobs," show mint marks from Lima, dated 1707. They also have castles, lions, Jerusalem crosses, and other Spanish imperial symbols imprinted on them.
'The finding of cobs...points to a vessel navigating the Tierra Firme route in the early 18th century," said the paper. "The San José galleon is the only ship that matches these characteristics.'
This Holy Grail of shipwrecks is now at the center of a legal battle. Colombia claims it is the sole owner of the wreck under its national heritage laws. They argue that as the ship lies within its territorial waters, it belongs to them. But others want to stake their claim over the ship and its $16 billion of treasure.
Spain contends that the San José is a Spanish ship and so it is Spanish state property. Sea Search Armada says it was the first to identify the general location of the wreck in the 1980s and so should receive some of the compensation. Indigenous communities from countries like Peru and Bolivia are also asserting claims to the treasure since most of it was pillaged from them when they were under Spanish colonial rule.
After hearings in Colombia and the U.S., the decision about who owns the most valuable shipwreck in the world will lie with the Permanent Court of Arbitration at the Hague.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Escape from reality with ‘The Librarians: The Next Chapter' this weekend
Escape from reality with ‘The Librarians: The Next Chapter' this weekend

Los Angeles Times

time6 hours ago

  • Los Angeles Times

Escape from reality with ‘The Librarians: The Next Chapter' this weekend

Welcome to Screen Gab the newsletter for everyone who needs a break from doomscrolling. If your brain needs a fantasy adventure to escape the realities of life, perhaps the escapades of a time-traveling librarian will suit your needs. 'The Librarians,' which started as a trio of TV movies that evolved into a four-season TV series, has built out its universe with the recent spinoff 'The Librarians: The Next Chapter.' Showrunner Dean Devlin stopped by Guest Spot to discuss how the new show connects to the wider franchise. And if you're into crime dramas as a form of escapist TV, this week's streaming recommendations include a new British detective drama that features a mismatched crime-solving duo and the prequel series in 'Dexter's' expanding serial killer universe. Must-read stories you might have missed 50 years after Marshal Matt Dillon's last draw, 'Gunsmoke' is a streaming hit: The adult western drama with James Arness is finding loyal fans and new audiences on Peacock, Paramount+ and Pluto TV. Commentary: Why on earth is Dr. Phil involved in immigration raids? Another made-for-TV event from a reality star president: Of all the alarming things that have happened in L.A., Dr. Phil hanging out with Trump's top border policy advisor during immigration raids was the weirdest. In 'Murderbot,' an anxious scientist and an autonomous robot develop a workplace-trauma bond: Alexander Skarsgård and Noma Dumezweni, co-stars of Apple TV+'s 'Murderbot,' discuss Episode 6 of the sci-fi series and the autism-coded robot at the center of the show. 'Materialists' is a smart and funny all-star love triangle with its own commitment issues: In Celine Song's rom-com follow-up to her Oscar-nominated 'Past Lives,' Pedro Pascal is rich, Chris Evans is poor and Dakota Johnson is a matchmaking mercenary. Recommendations from the film and TV experts at The Times 'Death Valley' (BritBox) Set not in our own dry desert but the verdant valleys of Wales, this adorable and comical mystery series from the great Timothy Spall, OBE — longtime favorite of director Mike Leigh and familiar to many as Peter Pettigrew in five 'Harry Potter' movies — stars as John Chapel, a former TV police detective living in small-town isolation after the death of his Welsh wife. Along comes Gwyneth Keyworth as the world's sweetest (actual) police detective Janie Mallowan, Chapel's biggest fan who knocks on his door in the middle of an investigation. After some back-and-forth, push and pull, they become one of those pro-am teams that figure in so many detective shows — like 'Castle,' without the sex — and never better done than here. Chapel takes to the job in grand thespian style, playing characters, improvising and analyzing motives through character analysis. (He's not always right.) Janie is alternately stressed and impressed. Backdrops for the cases include a local theater production, a walking group, a wedding and a school reunion — cozy stuff. — Robert Lloyd 'Dexter: Original Sin' (Paramount+ with Showtime) If superheroes can have origin stories, why not serial killers carrying on their secret mission of justice? That's the concept of Showtime's 'Dexter: Original Sin,' which travels back to 1991 to show how the crafty Dexter Morgan, the forensics specialist who moonlighted as a vigilante, began his killing ways while working as an intern at the Miami Metro Police Department. The series premiered last year as a prequel spinoff of 'Dexter,' the popular drama/dark comedy that ran for eight seasons and later continued its story in the sequel series 'Dexter: New Blood.' Patrick Gibson uncannily captures the mannerisms, facial expressions and inflections of 'Dexter' star Michael C. Hall, who provides the trademark narration that was one of the signatures of the original series. The show is the perfect appetizer for the July 11 premiere of 'Dexter: Resurrection,' which brings the titular antihero back to life despite being 'shot to death' by his son Harrison (Jack Alcott) in the finale of 'Dexter: New Blood.' — Greg Braxton A weekly chat with actors, writers, directors and more about what they're working on — and what they're watching 'The Librarians' is back after more than seven years, but things are a little different from when we last visited this fantasy land, which spanned three films (starring Noah Wyle) and a four-season TV series. In its latest iteration, 'The Librarians: The Next Chapter,' we're introduced to a new librarian named Vikram Chamberlain (Callum McGowan), who time-traveled from 1847 and now finds himself stuck in the present. He returns to his castle in Belgrade, Serbia only to find that it's now a museum — but more notably, his arrival releases magic across the continent, leading to some strange occurrences. He has to clean up the mess, with some help in the form of guardian Charlie (Jessica Green), scientist Lysa (Olivia Morris) — who inherited the castle — and historian Connor (Bluey Robinson). For fans of the original series, Christian Kane makes a guest appearance as librarian Jacob Stone. Also returning is showrunner and executive producer Dean Devlin, who is carrying the torch on the series. He stopped by Screen Gab to talk about the new season, which currently airs on TNT and is also available for streaming on TNT's website and app, — Maira Garcia 'The Librarians' has amassed a legion of loyal fans over the years, first with the films and then with the series. What made you decide to return to it and how did you approach developing 'The Next Chapter' with a new cast? Honestly, I never wanted to stop telling stories in the world of the magical Library! When an opportunity came up to continue the franchise, I jumped at it. I didn't want to reboot the story, because in my mind (and the fans) the original team of Librarians are still out there doing missions. I wanted to focus on a different story that takes place in parallel. When the idea of a Librarian from the past appearing today, it felt like just the right 'fish out of water' story we needed to kick off a new series. The series features this push and pull of logic and magic, history and fantasy. How do you juggle history with the supernatural elements of the show? It's really important to us that viewers can Google things we talk about in our show. While we may not follow exactly the legends in the zeitgeist, we wanted there to be enough of a connection to deepen the enjoyment of our adventures. So history and mythology are at the heart of our show. Sometimes we'll give an alternate perspective or backstory, but there is always a nugget [of] connection to the stories we want to tell. Throughout your career, you've worked on a number of sci-fi and fantasy films and series like 'Stargate,' 'Independence Day' and 'The Ark.' What is it about these genres that appeals to you, and why do you think audiences gravitate toward them? Often 'escapist' entertainment is looked down upon as a lesser art form. But I find that audiences, especially after dealing with things like a pandemic, economic and personal hardships, [or] political divisions, have a real NEED to escape into a world of optimism and wonder and adventure. I'm no exception. What have you watched recently that you're recommending to everyone you know? It's not super recent, but I've loved watching 'Only Murders in the Building' [Hulu], 'Ted Lasso' [AppleTV+], 'Star Trek: Strange New Worlds,' 'Star Trek: Picard' (especially season 3) [both on Paramount+] and the new 'Doctor Who' [Disney+]. What's your go-to comfort watch, the film or TV show you return to again and again? If 'Tombstone' or 'Enter the Dragon' is playing on late-night TV, then I'm not getting any sleep. And of course, the 10th and 11th Doctors on 'Doctor Who' are a constant fallback watch for me.

‘Transformative': the UK lab working on a way to halt genetic type of dementia
‘Transformative': the UK lab working on a way to halt genetic type of dementia

Yahoo

time7 hours ago

  • Yahoo

‘Transformative': the UK lab working on a way to halt genetic type of dementia

Behind the gleaming glass facade of an office block in east London's Docklands, Dr Martina Esposito Soccoio is pipetting ribonucleic acid into test tubes. Here, not far from Canary Wharf's multinational banks, a British university spinout is working on a breakthrough treatment for a form of dementia that affects millions of people worldwide. There is no cure for dementia at present, but scientists at AviadoBio hope their clinical studies can stop the progression of a particular genetic type of frontotemporal dementia (FTD). 'It may be one of the first dementias to have a definitive treatment, a cure if you like, a really transformative treatment that allows people to live much longer and much more normal lives,' says Prof James Rowe, a consultant neurologist at Cambridge's Addenbrooke's hospital who is involved in the UK trial. FTD mainly affects the front and sides of the brain and, unlike Alzheimer's disease, does not begin with memory loss, which tends to occur later. It is characterised by progressive loss of language and changes in personality and behaviour. Most cases are diagnosed in people aged 45 to 65, but it can affect those in their 20s and 30s. There are an estimated 20,000 to 40,000 people living with FTD in the UK, and between 1 million and 2 million in the world. Rowe says: 'It's a double-edged sword: the young onset, the high genetic burden and rapid illness are also features that perhaps make it more tractable to treat.' The Die Hard and Pulp Fiction actor Bruce Willis, who recently celebrated his 70th birthday, was diagnosed two years ago with FTD, which his family described as a 'cruel disease'. They have not said whether he has a genetic form of FTD. The gene therapy developed by AviadoBio, which was spun out of Prof Christopher Shaw's research lab at King's College London in 2021, targets a type of FTD known as FTD-GRN. This is caused by mutations of a gene that lead to a deficiency of progranulin (GRN), a protein that is essential for maintaining healthy brain cells. AviadoBio, which employs 60 people, signed an exclusive licence agreement with the Japanese pharmaceutical firm Astellas last October to develop the therapy. It is now recruiting patients for its clinical trial in the UK, as well as the US, Poland, Spain, Sweden and the Netherlands. The infusion was administered in Warsaw in March 2024 in one of six patients who have had the treatment so far, in Poland and the US. All patients will be followed for up to five years as part of the trial. AviadoBio expects to publish the first data next year. Three years ago, Jessica Crawford, from Beverley in East Yorkshire, lost her mother, Julia, to FTD, caused by mutations of another gene, C9orf72. In 2014, when Julia was 58, her behaviour changed; the family suspected depression. Previously very sociable, she stopped going out and started playing games such as Candy Crush or watching TV shows 'over and over', her daughter recounts. Her mother initially did not want to see a doctor, and was only diagnosed with FTD in February 2019. By this time she was so confused she once put raw chicken in a sandwich. 'Getting the diagnosis wasn't easy because FTD wasn't well known; my mum was acing in the memory tests,' Jessica says. Julia became increasingly confused and lost the ability to speak, and then to communicate at all. Jessica became her full-time carer in 2020, but her mother deteriorated so much that she had to enter a care home in late 2021, and died the following year. Jessica, 33, found out she also carries the gene mutation, and with her husband decided to conceive through IVF with a pre-implantation genetic diagnosis. When their five embryos were screened, four had the gene mutation, and the fifth resulted in the birth of their son. The couple donated their other four embryos to science and she takes part in GENFI – a long-running UK-led global study of families with FTD across 40 sites. AviadoBio itself was born out of the research done at King's by Shaw, a neurologist who has focused on FTD and amyotrophic lateral sclerosis (ALS) for more than three decades, and Dr Youn Bok Lee and Dr Do Young Lee from the UK Dementia Research Institute's centre based at King's. ALS, the most common form of motor neurone disease, has also been linked to mutations of the GRN gene and leads to muscle weakness, paralysis and eventually death. Shaw acts as the company's chief scientific and clinical adviser, and while the Lees are no longer involved in the firm's research, all three remain shareholders. David Cooper, AviadoBio's chief medical officer, says: 'It was something that hit me when I first joined the company, [when] you look at the MRI scans of patients with a GRN mutation, the frontal and temporal parts of their brain are just melting away … So we really need earlier treatment, an earlier diagnosis and a more organised healthcare approach to deal with it.' AviadoBio's lead product, AVB-101, is infused directly into the brain by a neurosurgeon using a cannula as thin as a strand of angel hair pasta, during a 90-minute procedure guided by MRI. It delivers a functional copy of the progranulin gene to restore appropriate levels of the protein to affected areas of the brain. It is a one-off treatment, and no immunosuppressant drugs are needed afterwards. 'The patients who have FTD are born with almost half of the progranulin levels that you and I might have,' says the chief executive, Lisa Deschamps. 'Our goal in the study is to supplement the GRN gene and restore as much progranulin in these individuals as possible to normal levels to reduce the neurodegeneration effect.' Other medications in development around the world include two gene therapies, from Philadelphia-based Passage Bio and Eli Lilly-owned Prevail Therapeutics, but they do not target the thalamus, the 'relay station' in the brain. Passage Bio's therapies are delivered directly to the cerebrospinal fluid in a single treatment. Denmark's Vesper Bio has developed an oral capsule, designed to act on the GRN gene, that is being trialled at University College London hospital. AviadoBio, whose investors include Johnson & Johnson's innovation arm and the UK not-for-profit LifeArc Ventures, is part of a growing life science cluster in Canary Wharf. At its labs, scientists – assisted by robotics – research how to target a particular gene. 'The UK has real strengths in this area,' says Rowe, pointing to the international GENFI study, run since 2011 by Prof Jonathan Rohrer, a neurologist from UCL Queen Square Institute of Neurology who also sits on AviadoBio's scientific advisory board. 'It's a real win for the UK.'

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

Yahoo

time10 hours ago

  • Yahoo

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving AstraZeneca and Third Harmonic Bio, as well as updates from UCB, UroGen Pharma and Insmed that you may have missed. AstraZeneca on Friday formed a new collaboration with Shijiazhuang City, China-based CSPC Pharmaceutical Group, this time to use the firm's AI technology to discover oral drugs for immunological diseases and other unspecified chronic conditions. CSPC will get $110 million in upfront cash and is eligible to receive up to $5.2 billion in additional development and sales milestones. The alliance builds on a 2024 deal that handed AstraZeneca an oral, lipid-lowering therapy, and deepens the British drugmaker's investment in China. In March, the company committed $2.5 billion to a research and development center in Beijing and formed collaborations with three China-based biotechs. — Ben Fidler Belgian drugmaker UCB said on Thursday that it plans to build a new biologics manufacturing plant in the U.S. UCB is currently running a "feasibility study" to determine the ideal U.S. location for the coming facility, but said in a statement that, once operational, it should create about 300 jobs in biologics manufacturing and have an economic impact of around $5 billion. The company currently employs close to 2,000 workers in the U.S. — Ben Fidler Stockholders of Third Harmonic Bio have voted in support of a liquidation plan expected to see them recoup anywhere from $5.30 to $5.44 for each share they own. The company also said Thursday that it's beginning an auction for an experimental drug for chronic hives that's ready for Phase 2 testing. Proceeds from that auction, as well as sales of any other remaining assets, could boost stockholder payouts beyond current estimates. Third Harmonic raised $185 million in a 2022 initial public offering, but its share price plummeted shortly afterwards following a clinical setback. — Ben Fidler Insmed has raised $750 million in a public stock offering, quickly cashing in on positive Phase 2 study results that pushed its market value past $16 billion. The company on Wednesday sold 7,812,500 shares of its common stock at $96 apiece, raising more than it initially projected. Insmed shares climbed by a third this week after mid-stage results indicated its experimental drug could be superior to an inhalable pulmonary arterial hypertension medicine that's sold by United Therapeutics and could reach almost $2 billion in sales this year. The company expects to start a pair of Phase 3 trials later this year and early next. — Ben Fidler The Food and Drug Administration bypassed the advice of one of its expert panels in approving a drug Urogen Pharma has been developing for a form of bladder cancer. The therapy, a formulation of the chemotherapy mitomycin, was cleared on Thursday and will be sold as Zusduri for a recurrent type of non-muscle invasive bladder cancer. FDA advisers last month determined by a slim, 5-4 margin, that the drug's benefits didn't outweigh the risks of treatment. UroGen shares surged more than 60% since the announcement. — Ben Fidler Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store